315 related articles for article (PubMed ID: 27481554)
1. NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates.
de Castro Barbosa ML; da Conceicao RA; Fraga AGM; Camarinha BD; de Carvalho Silva GC; Lima AGF; Cardoso EA; de Oliveira Freitas Lione V
Anticancer Agents Med Chem; 2017; 17(4):483-490. PubMed ID: 27481554
[TBL] [Abstract][Full Text] [Related]
2. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
4. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M; Alimena G
Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB as a potential molecular target for cancer therapy.
Lee CH; Jeon YT; Kim SH; Song YS
Biofactors; 2007; 29(1):19-35. PubMed ID: 17611291
[TBL] [Abstract][Full Text] [Related]
6. NF-κB and the link between inflammation and cancer.
DiDonato JA; Mercurio F; Karin M
Immunol Rev; 2012 Mar; 246(1):379-400. PubMed ID: 22435567
[TBL] [Abstract][Full Text] [Related]
7. Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals.
Cvek B; Dvorak Z
Curr Pharm Des; 2007; 13(30):3155-67. PubMed ID: 17979756
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to target NF-κB and other signaling pathways in cancer stem cells.
Ukaji T; Umezawa K
Adv Biol Regul; 2014 Sep; 56():108-15. PubMed ID: 25128192
[TBL] [Abstract][Full Text] [Related]
9. Using NF-κB as a molecular target for theranostics in radiation oncology research.
Liu YC; Chiang IT; Hsu FT; Hwang JJ
Expert Rev Mol Diagn; 2012 Mar; 12(2):139-46. PubMed ID: 22369374
[TBL] [Abstract][Full Text] [Related]
10. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.
Fuchs O
Curr Mol Pharmacol; 2010 Nov; 3(3):98-122. PubMed ID: 20594187
[TBL] [Abstract][Full Text] [Related]
12. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
13. Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.
Zhang Z; Huang L; Zhao W; Rigas B
Cancer Res; 2010 Mar; 70(6):2379-88. PubMed ID: 20215502
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor growth by NF-kappaB inhibitors.
Umezawa K
Cancer Sci; 2006 Oct; 97(10):990-5. PubMed ID: 16925581
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V; Vaiyapuri T; Tergaonkar V
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708302
[TBL] [Abstract][Full Text] [Related]
16. NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives.
Freitas RHCN; Fraga CAM
Curr Drug Targets; 2018; 19(16):1933-1942. PubMed ID: 29468963
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Ciucci A; Gianferretti P; Piva R; Guyot T; Snape TJ; Roberts SM; Santoro MG
Mol Pharmacol; 2006 Nov; 70(5):1812-21. PubMed ID: 16908599
[TBL] [Abstract][Full Text] [Related]
18. Heteronemin, a spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B activation through proteasome inhibition and induces apoptotic cell death.
Schumacher M; Cerella C; Eifes S; Chateauvieux S; Morceau F; Jaspars M; Dicato M; Diederich M
Biochem Pharmacol; 2010 Feb; 79(4):610-22. PubMed ID: 19814997
[TBL] [Abstract][Full Text] [Related]
19. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.
Wen D; Nong Y; Morgan JG; Gangurde P; Bielecki A; Dasilva J; Keaveney M; Cheng H; Fraser C; Schopf L; Hepperle M; Harriman G; Jaffee BD; Ocain TD; Xu Y
J Pharmacol Exp Ther; 2006 Jun; 317(3):989-1001. PubMed ID: 16525037
[TBL] [Abstract][Full Text] [Related]
20. NF-κB in cancer therapy.
Li F; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Arch Toxicol; 2015 May; 89(5):711-31. PubMed ID: 25690730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
